Standout Papers

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art 2020 2026 2022 2024877
  1. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020)
    Michael A. Nauck, Daniel R. Quast et al. Molecular Metabolism
  2. The evolving story of incretins ( GIP and GLP ‐1) in metabolic and cardiovascular disease: A pathophysiological update (2021)
    Michael A. Nauck, Daniel R. Quast et al. Diabetes Obesity and Metabolism

Immediate Impact

2 from Science/Nature 87 standout
Sub-graph 1 of 21

Citing Papers

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025 Standout
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
2025 Standout
1 intermediate paper

Works of Daniel R. Quast being referenced

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
2020 Standout

Author Peers

Author Last Decade Papers Cites
Daniel R. Quast 967 437 106 469 30 1.4k
Leona Plum‐Mörschel 1113 590 76 409 48 1.4k
Florian M.M. Baeres 822 405 106 438 30 1.6k
Freddy G. Eliaschewitz 1516 613 104 707 42 1.9k
Mark Warren 1728 619 85 714 30 1.9k
Antoine Makdissi 996 430 30 261 31 1.3k
Holbrooke S. Seltzer 1027 525 85 423 29 1.7k
C. J. HLAD 742 536 76 305 27 1.3k
Santiago Tofé 987 330 85 467 40 1.2k
Mustafa Kemal Balcı 889 674 67 328 72 1.8k
Stanley S. Schwartz 1357 557 47 662 63 2.2k

All Works

Loading papers...

Rankless by CCL
2026